During the past decades, the KOR has emerged as an alternative pharmacotherapeutic target; opposite to the MOR activation, the KOR does not mediate the rewarding effects or the respiratory depression, and it induces fewer gastrointestinal-related complications [7,16,17]. The gene discussed is OPRM1; the disease is Respiratory insufficiency due to muscle weakness.